Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-01-18
2011-11-01
Aulakh, Charanjit (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S280000
Reexamination Certificate
active
08048891
ABSTRACT:
The present invention relates to methods of treatment of non-Hodgkin's lymphomas. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.
REFERENCES:
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5681567 (1997-10-01), Martinez et al.
patent: 5736156 (1998-04-01), Burke
patent: 5840900 (1998-11-01), Greenwald et al.
patent: 5840973 (1998-11-01), Yasukohchi et al.
patent: 5859022 (1999-01-01), Hausheer et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 5902588 (1999-05-01), Greenwald et al.
patent: 5948155 (1999-09-01), Yui et al.
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 6011042 (2000-01-01), Greenwald et al.
patent: 6111107 (2000-08-01), Greenwald et al.
patent: 6121451 (2000-09-01), Henegar et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6177087 (2001-01-01), Greenwald et al.
patent: 6194580 (2001-02-01), Greenwald et al.
patent: 6281223 (2001-08-01), Choy et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6395266 (2002-05-01), Martinez et al.
patent: 6403569 (2002-06-01), Achterrath
patent: 6461603 (2002-10-01), Bentley et al.
patent: 6534293 (2003-03-01), Barany et al.
patent: 6608076 (2003-08-01), Greenwald et al.
patent: 6632818 (2003-10-01), Dinsmore et al.
patent: 6638499 (2003-10-01), Martinez et al.
patent: 6649778 (2003-11-01), Zhao et al.
patent: 6723338 (2004-04-01), Sarris et al.
patent: 6737505 (2004-05-01), Bentley et al.
patent: 6756037 (2004-06-01), Greenwald et al.
patent: 6875841 (2005-04-01), Sakanoue et al.
patent: 6897200 (2005-05-01), Burke et al.
patent: 7462627 (2008-12-01), Zhao et al.
patent: 7671067 (2010-03-01), Sapra
patent: 7723351 (2010-05-01), Zhao et al.
patent: 2001/0041172 (2001-11-01), Bentley et al.
patent: 2002/0002250 (2002-01-01), Bentley et al.
patent: 2002/0016285 (2002-02-01), Bhatt et al.
patent: 2002/0077279 (2002-06-01), Kumar et al.
patent: 2002/0182172 (2002-12-01), Bentley et al.
patent: 2003/0105275 (2003-06-01), Bentley et al.
patent: 2004/0009229 (2004-01-01), Unger et al.
patent: 2004/0058981 (2004-03-01), Lai et al.
patent: 2004/0077595 (2004-04-01), Cheng et al.
patent: 2004/0156858 (2004-08-01), Franzusoff et al.
patent: 2004/0247624 (2004-12-01), Unger et al.
patent: 2005/0112088 (2005-05-01), Zhao et al.
patent: 2005/0214250 (2005-09-01), Harris et al.
patent: 2005/0226843 (2005-10-01), Bentley et al.
patent: 2006/0135527 (2006-06-01), Houghton et al.
patent: 2007/0173615 (2007-07-01), Zhao et al.
patent: 2007/0259375 (2007-11-01), Ford et al.
patent: 2008/0058364 (2008-03-01), Sapra
patent: 2008/0193408 (2008-08-01), Zhao et al.
patent: 2009/0074704 (2009-03-01), Zhao et al.
patent: 0757049 (1999-03-01), None
patent: 9623794 (1996-08-01), None
patent: 9841562 (1998-09-01), None
patent: 0064486 (2000-11-01), None
patent: 0168066 (2001-09-01), None
patent: 0174402 (2001-10-01), None
patent: 02089789 (2002-11-01), None
patent: 03031467 (2003-04-01), None
patent: 03037384 (2003-05-01), None
patent: 03037385 (2003-05-01), None
patent: 2004060967 (2004-07-01), None
patent: 2005028539 (2005-03-01), None
patent: 2007031091 (2007-03-01), None
patent: 2007092646 (2007-08-01), None
Office Action issued in U.S. Appl. No. 11/840,773 and dated May 7, 2009.
International Search Report and Written Opinion issued in PCT/US08/53438 and dated Oct. 17, 2008.
International Search Report and Written Opinion issued in PCT/US09/55319 and dated Dec. 31, 2009.
Nemunaitis et al., Irinotecan Hydrochloride (CPT-11) Resistance Identified by K-ras Mutation in Patients with Progressive Colon Cancer After Treatment with 5-Fluorouracil (5-FU) American Journal of Clinical Oncology, Oct. 1997, 20(5):527-529.
Allen et al., Role of Genomic Markers in Colorectal Cancer Treatment, JJ Clin Oncol Apr. 12, 2005, 23(20):4545-4552.
Padilla de Jesus et al., Polyester Dendritic Systems for Drug Delivery Applications: in Vitro and in Vivo Evaluation, Bioconjugate Chem. 13:453-461, 2002.
Warnecke et al., Maleimide-oligo(ethylene glycol) derivatives of Camptothecin as Albumin-Binding Prodrugs: Synthesis and Antitumor Efficacy, Bioconjugate Chem. 14:377-387, 2003.
International Search Report and Written Opinion issued in PCT/US07/76241 and dated Aug. 8, 2008.
International Search Report and Written Opinion dated Aug. 13, 2008 issued in PCT/US07/03808.
Zalipsky et al., Attachment of Drugs to Polyethylene Glycols, European Polymer Journal, 1983, 19:1177-1183.
Greenwald et al., Poly(ethylene glycol) Conjugated Drugs and Prodrugs: A Comprehensive Review, Critical Review in Therapeutic Drug Carrier Systems, 2000, 17:101-161.
Carpino et al., New family of base- and nucleophile-sensitive amino-protecting groups. A Michael-acceptor-based deblocking process. Practical utilization of the 1,1-dioxobenzo[b]thiophene-2-ylmethylcarbonyl (Bsmoc) group, Journal of the American Chemical Society, 119: 9915-9916, 1997.
Chabot, G.G., Clinical pharmacokinetics of irinotecan, Clinical Pharmacokinet, 33:245-259, 1997.
Choe et al., Anticancer drug delivery systems: N4-acyl-poly(ethyleneglycol) prodrugs of ara-C. I. Efficacy in solid tumors, Journal of Controlled Release, 79:41-53, 2002.
Conover et al., Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker, Cancer Chemotherapy Pharmacology, 407-414, 1998.
Duncan, R., Polymer conjugates as anticancer nanomedicines, Nature Reviews: Cancer, 6:688-701, 2006.
Garcia-Carbonero, R., et al., Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins, Clinical Cancer Research, 8:641-662, 2002.
Gottlieb et al., Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880), Cancer Chemotherapy Reports, 54: 461-470, 1970.
Greenwald et al., Synthesis, isolation, and characterization of 2′-paclitaxel glycinate: an application of the Bsmoc protecting group, Journal of Organic Chemistry, 68:4894-6, 2003.
Greenwald, et al., Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms, Journal of Medicinal Chemistr, 39: 1938-1940, 1996.
Greenwald et al., Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs—Design and in vivo effectiveness, Journal of Medicinal Chemistry, 39: 424-431, 1996.
Greenwald et al., Effective drug delivery by PEGylated drug conjugates, Advanced Drug Delivery Reviews, 55:217-250, 2003.
Kaneda, N., et al., Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse, Cancer Research, 50: 1715-1720, 1990.
Kawato et al., Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11, Cancer Research, 51:4187-4191, 1991.
Liu et al., Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions, Journal of Pharmaceutical and Biomedical Analysis, 35:1113-1125, 2004.
Maeda et al., Tumor vascular permeability and the EPR effect in macromolecular therpeutics: a review, Journal of Controlled Release, 65:271-284, 2000.
Mathijssen, R.H.J., et al., Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), Clinical Cancer Research, 7:2182-2194, 2001.
Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond, Nature Reviews: Cancer, 6: 789-802, 2006.
Rowinsky et al., A Phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies, Journal of Clinical Oncology, 148-157, 2003.
Senter et al., Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug, Bioconjugate Chemistry, 12:1074-1080, 2001.
Slatter, J.G., et al., Bioactivation of the anticancer agent CPT-11 to SN38 by human hepatic microsomal carboxylesterases and the in vitro assessment
Aulakh Charanjit
Enzon Pharmaceuticals, Inc.
Lucas & Mercanti LLP
LandOfFree
Treatment of non-hodgkin's lymphomas with multi-arm... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of non-hodgkin's lymphomas with multi-arm..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of non-hodgkin's lymphomas with multi-arm... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286240